Hypertrophic Cardiomyopathy - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for hypertrophic cardiomyopathy including molecules at pre-clinical, Phase II, Phase III, and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, by territory, therapeutic modality, and target.

Overview of the drug development pipeline for hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) occurs due to the thickening of the walls of the heart that reduces the effectiveness of the heart to pump blood. This thickening of the walls is termed as hypertrophy and this condition can lead to heart failure and heart attack. HCM has numerous symptoms such as irregular heartbeat, shortness of breath, fatigue, and syncope (fainting). Technavio’s market research analysts have predicted that due to the genetic nature of this disease, players in the pharmaceutical industry are focusing extensively for significant drug development of therapeutics for hypertrophic cardiomyopathy in the forthcoming years.

Our market research analysts have also identified that most of the drug development molecules in the pipeline are under the discovery drug development stage. Our market research analysts have also identified that almost same amount of drug molecules are under the pre-clinical and phase II drug development stage. The pipeline landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in the phase I stage.    

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of hypertrophic cardiomyopathy. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• MIRAGEN THERAPEUTICS
• MYOKARDIA  
• DORMANT DRUGS

Therapeutic assessment of the drug development pipeline for hypertrophic cardiomyopathy by route of administration

• Oral

The oral route of administration (ROA) involves the administration of drug substances through mouth cavity. It has been observed that in this pipeline, therapeutics such as Perhexiline and Mavacamten are being developed for oral administration.  

Therapeutic assessment of the drug development pipeline for hypertrophic cardiomyopathy by therapeutic modality

• Small molecule
• Gene therapy 

According to this pipeline analysis report, majority of the molecules that are currently in the drug development pipeline for hypertrophic cardiomyopathy are being developed as small molecules. These molecules are chemically manufactured active substances, with low molecular weight that effectively enter cells, and combine with specific biological macromolecules and act as an effector and alter the activity of the target cell.

Technavio also offers customization on reports based on specific client requirement.